Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, N. R.
Right arrow Articles by Krauss, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, N. R.
Right arrow Articles by Krauss, G. L.
Neurology 1999;53:2082
© 1999 American Academy of Neurology
Articles

Visual dysfunction in patients receiving vigabatrin

Clinical and electrophysiologic findings N. R. Miller, MD, M. A. Johnson, PhD, S. R. Paul, C. A. Girkin, MD, J. D. Perry, MD, M. Endres and G. L. Krauss, MD

From the Neuro-Ophthalmology Unit (Drs. Miller, Girkin, and Perry, and M. Endres) and the Department of Neurology (Drs. Miller and Girkin, and S.R. Paul), the Johns Hopkins Medical Institutions, Baltimore, and the Maryland Center for Eye Care (Dr. Johnson), University of Maryland, Baltimore.

Address correspondence and reprint requests to Dr. N.R. Miller, Maumenee B-109, The Wilmer Eye Institute, 600 North Wolfe Street, Baltimore, MD 21287-9204.

BACKGROUND: Vigabatrin is an antiepileptic drug that, although relatively well tolerated, is associated with visual field constriction and other visual disturbances of unclear origin.

METHODS: We performed a complete neuroophthalmologic examination and electrophysiologic studies on 39 patients receiving vigabatrin and on 11 control patients.

RESULTS: Nearly 50% of patients receiving vigabatrin had constricted visual fields compared with control patients. Some of the vigabatrin patients also had reduced visual acuity and abnormal color vision. In addition, most vigabatrin patients had abnormal electroretinographic results, the severity of which correlated strongly with the degree of visual field constriction.

CONCLUSIONS: Vigabatrin can cause electrophysiologic evidence of retinal dysfunction and clinically detectable disturbances of visual sensory function.

Key words: Seizures—Vigabatrin—Visual fields—Perimetry—Electroretinogram—{gamma}-Aminobutyric acid.




This article has been cited by other articles:


Home page
 IOVSHome page
S. Durbin, G. Mirabella, J. R. Buncic, and C. A. Westall
Reduced Grating Acuity Associated with Retinal Toxicity in Children with Infantile Spasms on Vigabatrin Therapy
Invest. Ophthalmol. Vis. Sci., August 1, 2009; 50(8): 4011 - 4016.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
G. Mirabella, S. Morong, J. R. Buncic, O. C. Snead, W. J. Logan, S. K. Weiss, M. Abdolell, and C. A. Westall
Contrast Sensitivity Is Reduced in Children with Infantile Spasms
Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3610 - 3615.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
R. Werth and G. Schadler
Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin.
Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 3028 - 3035.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
J. M. Wild, C. R. Robson, A. L. Jones, I. A. Cunliffe, and P. E. M. Smith
Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer.
Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 917 - 924.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. McDonagh, L.J. Stephen, F.M. Dolan, S. Parks, G.N. Dutton, K. Kelly, D. Keating, G.J. Sills, and M.J. Brodie
Peripheral retinal dysfunction in patients taking vigabatrin
Neurology, December 23, 2003; 61(12): 1690 - 1694.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. F.A. Harding, E. L. Spencer, J. M. Wild, M. Conway, and R. L. Bohn
Field-specific visual-evoked potentials: Identifying field defects in vigabatrin-treated children
Neurology, April 23, 2002; 58(8): 1261 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
R Koul, A Chacko, A Ganesh, S Bulusu, and K Al Riyami
Vigabatrin associated retinal dysfunction in children with epilepsy
Arch. Dis. Child., December 1, 2001; 85(6): 469 - 473.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
J Ravindran, P Blumbergs, J Crompton, G Pietris, and H Waddy
Visual field loss associated with vigabatrin: pathological correlations
J. Neurol. Neurosurg. Psychiatry, June 1, 2001; 70(6): 787 - 789.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. L. Holmes, G. L. Krauss, and N. R. Miller
Using the electroretinogram to detect and monitor the retinal toxicity of anticonvulsants
Neurology, January 9, 2001; 56(1): 140 - 141.
[Full Text] [PDF]

Home page
 NeurologyHome page
N. R. Miller
Using the electroretinogram to detect and monitor the retinal toxicity of anticonvulsants
Neurology, August 8, 2000; 55(3): 333 - 334.
[Full Text] [PDF]

Home page
 NeurologyHome page
G. F. A. Harding, J. M. Wild, K. A. Robertson, S. Rietbrock, and C. Martinez
Separating the retinal electrophysiologic effects of vigabatrin: Treatment versus field loss
Neurology, August 8, 2000; 55(3): 347 - 352.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. A. Johnson, G. L. Krauss, N. R. Miller, M. Medura, and S. R. Paul
Visual function loss from vigabatrin: Effect of stopping the drug
Neurology, July 12, 2000; 55(1): 40 - 45.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
I F Comaish, C Gorman, N R Galloway, K. Manuchehri, A. Midelfart, and L V Wilton
Visual field defect associated with vigabatrin
BMJ, May 20, 2000; 320(7246): 1403 - 1403.
[Full Text]